Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Endocrinology
•
Bone and Calcium Disorders
•
Primary Care
For patients with eGFR around 30, do you still consider using reclast or evenity at adjusted doses?
Related Questions
Would you order a repeat DEXA scan 1 year later for a kidney transplant patient who had an initial DEXA scan within the first 6 months post-transplant showing osteopenia but no history of fractures, and who has been stable on glucocorticoid-free immunosuppressive therapy?
Does vitamin D supplementation in primary hyperparathyroidism increase the risk of kidney stones?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
How do you counsel patients on the likelihood of resolution of their hypertension post adrenalectomy for primary hyperaldosteronism?
Is there a role for monitoring PTH levels in patients with advanced chronic kidney disease who are receiving denosumab to assess for adynamic bone disease?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
Is there a role for calcitriol in dialysis patients regardless of PTH level?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
How do you approach management of osteoporosis in patients post lung transplant?
